Table 4 | Resistance Profile of Mutant Viruses Conferring..

Compoundsj	EC50 (nM)	Fold-Change in EC50 Relative to HIV-1 IIIb
Compoundsj	HIV-1 IIIb	T66I^a	L74M^b	E92Q^c	E92V^d	E138K^e	Q148K^f	V151A^g	N155H^h	N155Sⁱ	L74M/ E92V	E92V/ V151A	E138K/Q148K	E92V/G140S/V151A
RAL	4.3	1.9	1.7	6	7	1	136	4	24	43	15	31	747	166
GS-9160	1.7	1.9	1	26	17	1	28	10	61	36	56	126	676	689
GS-9224	5.6	1	1	21	7	1	42	5	110	65	25	73	419	438

^a Selected by L-708,906 (30, 32), S-1360 (31, 33) and EVG (37).
^b Selected by GS-9224 (this report), L-708,906 (32), S-1360 (33), L-870,810 (42) and GS-9160 (19).
^cSelected by EVG (31) and L-870,810 (42).
^d Selected by GS-9160 (19).
^e Selected by S-1360 (33).
^f Selected by GS-9224 (this report), S-1360 (31) and RAL (14, 39).
^g Selected by GS-278012, an analog of GS-9160 (19).
^h Developed in SHIV (89.6P) infected Rhesus macaques treated with L-870,812 (34).
ⁱ Selected by S-1360 (31).
^j The EC₅₀ and fold-change represent the mean of a least two independent experiments performed in triplicate.

Table 4: Resistance Profile of Mutant Viruses Conferring Resistance to INSTIs.

Goto home»